Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant hepatitis E vaccine safety and immunogenicity trial
ACTRN12607000368437Phase 2Completed
- Sponsor
- Xiamen Wantai Biological Pharmacy
- Start
- Jan 2005
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised trial of HEV 239 in hepatitis E (HEV) (6 arms), sponsored by Xiamen Wantai Biological Pharmacy. Primary endpoint: Seroconversion rate of IgG antibody against hepatitis E virus. Started Jan 2005; status: completed.
02
Drugs
HEV 239
03
Conditions
hepatitis E (HEV)
Beyond the preview
Go deeper on ACTRN12607000368437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000368437.